View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 1, 2020

Pfizer-BioNTech Phase III Covid-19 vaccine trial starts in South Africa

Pfizer and BioNTech have started participant enrolment in a Phase III clinical trial of their Covid-19 vaccine candidate in South Africa.

Pfizer and BioNTech have started participant enrolment in a Phase III clinical trial of their Covid-19 vaccine candidate in South Africa.

The Phase III programme is set to enrol about 44,000 participants globally, with focus on trial population diversity, including those with chronic, stable HIV, hepatitis C or hepatitis B infection.

Designed to assess the safety and efficacy of the vaccine candidate, the trial will involve nearly 800 subjects at four sites across Gauteng, Limpopo and the Western Cape in South Africa.

The South African Health Products Regulatory Authority (Sahpra) granted regulatory approval for the trial on 22 September 2020.

Dr Essack Mitha has been appointed as the trial’s national principal investigator.

Dr Mitha said: “We are proud and excited to be given the opportunity to take part in this global research effort. South African patients will play a critical role in the fight against Covid-19.

“We are confident that the South African sites will contribute high-quality data to this ground-breaking study, and that medical science will prevail in this pandemic.”

Pfizer and BioNtech have already enrolled more than 35,000 volunteers worldwide, following the US Food and Drug Administration (FDA) approval.

Pfizer South Africa medical director Dr Bha Ndungane-Tlakula said: “As Pfizer, we are proud to be bringing this important study to the country, and to the African Continent, to add to the growing knowledge of this virus so we can find a lasting and sustainable solution to end this pandemic.”

Last month, Pfizer said that Phase III trial participants were experiencing mild-to-moderate side effects with its investigational Covid-19 vaccine candidate.

On an investor conference call, the company executives noted that more than 12,000 study participants had received a second dose of the vaccine candidate.

Pfizer added that it was continuously analysing the safety and tolerability of the candidate in its trial.

Related Companies

Free Report
img

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU